1. Home
  2. NEWT vs RCKT Comparison

NEWT vs RCKT Comparison

Compare NEWT & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NewtekOne Inc.

NEWT

NewtekOne Inc.

N/A

Current Price

$12.12

Market Cap

395.5M

Sector

Finance

ML Signal

N/A

Logo Rocket Pharmaceuticals Inc.

RCKT

Rocket Pharmaceuticals Inc.

N/A

Current Price

$5.28

Market Cap

503.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEWT
RCKT
Founded
1998
1999
Country
United States
United States
Employees
N/A
202
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
395.5M
503.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NEWT
RCKT
Price
$12.12
$5.28
Analyst Decision
Hold
Buy
Analyst Count
3
14
Target Price
$14.00
$29.65
AVG Volume (30 Days)
163.5K
2.7M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
6.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$12.45
N/A
P/E Ratio
$5.99
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.12
$2.19
52 Week High
$14.91
$8.91

Technical Indicators

Market Signals
Indicator
NEWT
RCKT
Relative Strength Index (RSI) 40.64 72.16
Support Level $11.72 $2.99
Resistance Level $12.41 $5.34
Average True Range (ATR) 0.47 0.38
MACD -0.07 0.09
Stochastic Oscillator 38.99 88.33

Price Performance

Historical Comparison
NEWT
RCKT

About NEWT NewtekOne Inc.

NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Share on Social Networks: